Latest Breaking News On - ரோஜர் பாடல் - Page 1 : comparemela.com
CytomX Therapeutics, inc (CTMX) Q2 2021 Earnings Call Transcript
fool.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fool.com Daily Mail and Mail on Sunday newspapers.
GlycoMimetics, inc (GLYC) Q2 2021 Earnings Call Transcript
fool.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fool.com Daily Mail and Mail on Sunday newspapers.
GlycoMimetics, inc (GLYC) Q2 2021 Earnings Call Transcript
fool.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fool.com Daily Mail and Mail on Sunday newspapers.
Evelo Biosciences, Inc. (EVLO) Q1 2021 Earnings Call Transcript Motley Fool Transcribing © The Motley Fool Logo of jester cap with thought bubble.
Evelo Biosciences, Inc. (NASDAQ: EVLO)
Q1 2021 Earnings Call
Good morning, and welcome to Evelo Biosciences conference call to discuss the first-quarter 2021 financial results and business highlights. [Operator instructions] Please be advised that this call is being recorded at the company s request. At this time, I d like to turn the call over to Jessica Cotrone of Evelo. Please proceed.
Jessica Cotrone
Vice President, Head of of Communications
Thank you. This morning we issued the press release that outlines the topics we plan to discuss today. This release is available at www.evelobio.com under the investors tab. Today in our call, we have Simba Gill, chief executive officer; Mark Bodmer, president of R&D and chief scientific officer; and Jonathan Zung, chief development officer.
Insider Buying Of Molecular Templates Stock Corresponds With Analyst Ratings
Kailas Salunkhe- April 20, 2021, 11:36 AM EDT SHARE ON:
MTEM) has seen multiple informed key insider purchases over the past few weeks.
Whenever insiders such as top management, board members, or significant stake owners add to their holdings, it could be a very positive signal for retail investors.
While all information within companies may not be public, regulations stipulate the timely disclosure of trades that are executed by corporate insiders. This often provides retail investors with important insights into the financial health of the company.
Over the past three weeks, Biotech Target NV, which holds a more than 10% stake in Molecular Templates, has purchased MTEM stock in 6 separate transactions including one today to the value of about $1.29 million.